Trends in the pharmacological treatment of benign prostatic hyperplasia in the UK from 1998 to 2016: a population-based cohort study.
Alpha-blockers
Benign prostatic hyperplasia
Drug utilization
Five-alpha reductase inhibitors
Pharmacoepidemiology
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
05
12
2019
accepted:
30
08
2020
pubmed:
11
9
2020
medline:
9
10
2021
entrez:
10
9
2020
Statut:
ppublish
Résumé
To describe trends in the pharmacological treatment of BPH in the United Kingdom (UK) from 1998 to 2016. We created a cohort of men with a diagnosis of BPH between 1998 and 2016 using the Clinical Practice Research Datalink. Using Poisson regression, we estimated annual prescription rates of 5αRIs, α-blockers, and combination therapy (5αRIs + α-blockers). Adherence was defined by a proportion of days covered > 80%. Our cohort included 192,640 men with BPH who generated 1,176,264 person-years (PYs) of follow-up. The mean age was 68.0 (standard deviation: 10.7) years. The prescription rate of all BPH medications during the study period was 347.6 per 100 PYs (95% CI 347.2-347.9). α-Blockers had the highest prescription rate (222.9 per 100 PYs, 95% CI 222.7-223.2); prescription rates of 5αRIs and combination therapy were 69.1 per 100 PYs (95% CI 69.0-69.3) and 55.5 per 100 PYs (95% CI 55.4-55.7), respectively. The prescription rate for combination therapy was 19 times greater in 2013-2016 than in 1998-2000 (rate ratio: 19.2, 95% CI 18.6-19.7), while the prescription rates for 5αRIs and α-blockers each doubled during this period (rate ratio: 1.86, 95% CI 1.84-1.88 and rate ratio: 2.02, 95% CI 2.01-2.04, respectively). The proportion of patients who were adherent at 1 year to 5αRIs (32.3%), α-blockers (44.0%), and combination therapy (45.6%) was low. The prescription rate of BPH medications increased substantially between 1998 and 2016 in the UK, with the greatest relative increase observed with combination therapy. Adherence to BPH medications was low in this population-based study.
Identifiants
pubmed: 32909173
doi: 10.1007/s00345-020-03429-z
pii: 10.1007/s00345-020-03429-z
doi:
Substances chimiques
5-alpha Reductase Inhibitors
0
Adrenergic alpha-Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2019-2028Subventions
Organisme : CIHR
ID : MOP-136946
Pays : Canada
Organisme : CIHR
ID : MOP-136946
Pays : Canada
Références
Bushman W (2009) Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am 36:403–415
doi: 10.1016/j.ucl.2009.07.003
FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. 2011. (Accessed July 13, 2017, at https://www.fda.gov/drugs/drugsafety/ucm258314.htm .)
Santos DJ (2012) Benign prostatic hyperplasia: clinical manifestations and evaluation. TechVascIntervRadiol 15:265–269
Yuan JQ, Mao C, Wong SY et al (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore) 94:e974
doi: 10.1097/MD.0000000000000974
McVary KT, Roehrborn CG, Avins AL et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803
doi: 10.1016/j.juro.2011.01.074
Oelke M, Bachmann A, Descazeaud A et al (2013) EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 64:118–140
doi: 10.1016/j.eururo.2013.03.004
Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). MedClinNorth Am 95:87–100
McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338:557–563
doi: 10.1056/NEJM199802263380901
Roehrborn CG (2011) Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin N Am 95:87–100
doi: 10.1016/j.mcna.2010.08.013
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441
doi: 10.1016/S0090-4295(02)01905-2
MacDonald D, McNicholas TA (2003) Drug treatments for lower urinary tract symptoms secondary to bladder outflow obstruction. Drugs 63:1947–1962
doi: 10.2165/00003495-200363180-00004
Hakimi Z, Johnson M, Nazir J, Blak B, Odeyemi IA (2015) Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data. Curr Med Res Opin 31:43–50
doi: 10.1185/03007995.2014.968704
Moon HW, Yang JH, Choi JB et al (2018) Prescription pattern of alpha-blockers for management of lower urinary tract symptoms/benign prostatic hyperplasia. Sci Rep 8:13223
doi: 10.1038/s41598-018-31617-w
Herrett E, Gallagher AM, Bhaskaran K et al (2015) Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol 44:827–836
doi: 10.1093/ije/dyv098
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the general practice research database: a systematic review. BrJClinPharmacol 69:4–14
National Institute for Health and Care Excellence (2010) Lower urinary tract symptoms in men: assessment and management. Clinical guideline 97. https://www.nice.org.uk/guidance/cg97 . Accessed 8 Sept 2020
Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099–1109
doi: 10.1016/j.eururo.2014.12.038
Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV (2007) The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51:207–215 (discussion 15-6)
doi: 10.1016/j.eururo.2006.06.012
Filson CP, Wei JT, Hollingsworth JM (2013) Trends in medical management of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 82:1386–1392
doi: 10.1016/j.urology.2013.07.062
Parsons JK, Dahm P, Köhler TS, Lerner LB, Wilt TJ Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. Available online: https://www.auajournals.org/doi/full/10.1097/JU.0000000000001298 . Accessed 8 Sept 2020
Nickel JC, Aaron L, Barkin J, Elterman D, Nachabé M, Zorn KC (2018) Canadian Urological Association guideline on male lower urinary tract symptoms/benign prostatic hyperplasia (MLUTS/BPH): 2018 update. Can Urol Assoc J 12:303–312
doi: 10.5489/cuaj.5616
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS (2016) Adverse effects and safety of 5-alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol 9:56–62
pubmed: 27672412
pmcid: 5023004
Fullhase C, Chapple C, Cornu JN et al (2013) Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol 64:228–243
doi: 10.1016/j.eururo.2013.01.018
Lepor H, Williford WO, Barry MJ et al (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 335:533–539
doi: 10.1056/NEJM199608223350801
Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 61:119–126
doi: 10.1016/S0090-4295(02)02114-3
McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398
doi: 10.1056/NEJMoa030656
Lukacs B, Cornu JN, Aout M et al (2013) Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study. Eur Urol 64:493–501
doi: 10.1016/j.eururo.2013.02.026
Zabkowski T, Saracyn M (2018) Drug adherence and drug-related problems in pharmacotherapy for lower urinary tract symptoms related to benign prostatic hyperplasia. J Physiol Pharmacol. https://doi.org/10.26402/jpp.2018.4.14
doi: 10.26402/jpp.2018.4.14
pubmed: 30552307
Nichol MB, Knight TK, Wu J, Barron R, Penson DF (2009) Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia. J Urol 181:2214–2221 (discussion 21-2)
doi: 10.1016/j.juro.2009.01.033
DeCastro J, Stone B (2008) Improving therapeutic outcomes in BPH through diagnosis, treatment and patient compliance. Am J Med 121:S27–33
doi: 10.1016/j.amjmed.2008.05.024